Kiran Mazumdar-Shaw is the force behind innovation-led global biopharmaceuticals major Biocon, which continues to break ground and grow. The company posted a 38% YoY rise in revenue at ₹11,550 crore in FY23 led by biosimilars (up 61%) and research services (up 31%). During the year, Biocon Biologics acquired the global biosimilar business of its partner Viatris for $3 billion, boosting its portfolio of immunosuppressants, specialty APIs, and generic formulation products. The last year has also seen Biocon launch new products in the U.S., increase market share for existing ones through new contracts, and enter into tie-ups with Zentiva in Europe and Farmanguinhos in Brazil for regional growth. The company that started in 1978 with three people in her garage is now 13,500 plus, and Mazumdar-Shaw continues to lead from the top. — Gina Krishnan